U.S. markets closed
  • S&P 500

    4,441.67
    +35.87 (+0.81%)
     
  • Dow 30

    35,120.08
    +225.96 (+0.65%)
     
  • Nasdaq

    14,714.66
    +172.88 (+1.19%)
     
  • Russell 2000

    2,167.60
    +35.18 (+1.65%)
     
  • Crude Oil

    62.25
    -1.44 (-2.26%)
     
  • Gold

    1,782.60
    -0.50 (-0.03%)
     
  • Silver

    22.97
    -0.26 (-1.12%)
     
  • EUR/USD

    1.1705
    +0.0023 (+0.20%)
     
  • 10-Yr Bond

    1.2600
    +0.0180 (+1.45%)
     
  • GBP/USD

    1.3617
    -0.0021 (-0.15%)
     
  • USD/JPY

    109.7400
    -0.0010 (-0.00%)
     
  • BTC-USD

    49,158.37
    +2,490.39 (+5.34%)
     
  • CMC Crypto 200

    1,224.01
    +35.62 (+3.00%)
     
  • FTSE 100

    7,087.90
    +29.04 (+0.41%)
     
  • Nikkei 225

    27,013.25
    -267.92 (-0.98%)
     

Why Endo International (ENDP) Stock Is Plunging On Friday?

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Shares of Endo International (NASDAQ: ENDP) came in crashing after The Wall Street Journal reported that the drugmaker had engaged Alvarez & Marsal to look into a potential financial restructuring.

  • The report of a potential restructuring is only the latest of woes Endo has faced related to a flood of opioid-related lawsuits.

  • Endo hasn't confirmed that it hired a financial restructuring advisor. However, the Journal stated that Endo brought in Alvarez & Marsal to explore options for reducing its litigation-related liabilities and debt load of more than $8 billion.

  • The company and Alvarez didn't immediately respond to requests for comment.

  • As of July, nearly 3,000 legal cases were pending against Endo from states, counties, cities, Native American tribes, and over 300 lawsuits from healthcare institutions.

  • Related: Opioid Settlement Of B Between Drug Companies, States.

  • Price Action: ENDP shares are down 35.7% at $2.29 during the market session on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.